Investors

2019 News

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
Jun 13, 2019CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
SEATTLE, June 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City. Presentation details: Event: JMP Securities Life Sciences Conference Date: Thursday, Jun. 20 Time: ... 
Printer Friendly Version
May 29, 2019CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
SEATTLE, May 29, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City. Presentation details: Event: Jefferies Global Healthcare Conference Date: Wednesday, Jun. 5 Time: ... 
Printer Friendly Version
May 02, 2019CTI BioPharma Reports First Quarter 2019 Financial Results
SEATTLE, May 2, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019. "Advancing our U.S. and European development program for pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia remains our top priority for 2019, and we anticipate multiple important milestone events for pacritinib this year," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. ... 
Printer Friendly Version
Apr 03, 2019CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
SEATTLE, April 3, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central. Presentation details: Event: 18th Annual Needham Healthcare Conference   Date: Wednesday, Apr. 10 ... 
Printer Friendly Version
Mar 13, 2019CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018. "The Company is focused on advancing its development program of pacritinib for the treatment for myelofibrosis patients with severe thrombocytopenia in the United States and Europe in 2019," commented Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. "Following the previously-announced completi... 
Printer Friendly Version
Mar 12, 2019CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19
SEATTLE, March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New York Grand Central. Presentation details: Event:           Oppenheimer's 29th Annual Healthcare Conference Date:              Tuesday... 
Printer Friendly Version
Feb 20, 2019CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
SEATTLE, Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel. Presentation details: Event: 8th Annual SVB Leerink Global Healthcare Conference ... 
Printer Friendly Version
Feb 11, 2019CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
SEATTLE, Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI BioPh... 
Printer Friendly Version
Feb 01, 2019CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
- Company announces continuation of PAC203 study following third interim review - SEATTLE, Feb. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), during which the Company learned that the committee ... 
Printer Friendly Version